GPC3 and hepatocellular carcinoma: Making use of this distinct feature of GPC3 in HCC, an anti-GPC3 antibody therapy or antibody-drug conjugate (ADC) could be used as a biological missile targeting the GPC3-expressing cells, including liver cancer cells [53] and CD90+CSCs.